News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
HENGRUI PHARMA's Hemofiltration Replacement Fluid of Sodium Citrate Approved for Launch
HENGRUI PHARMA (01276.HK)'s subsidiary, Fujian Shengdi Pharmaceutical, received notification from the National Medical Products Administration (NMPA) approving the market launc...
Reset
Send
The window will close in 5 seconds
HENGRUI PHARMA's Hemofiltration Replacement Fluid of Sodium Citrate Approved for Launch
Close
Recommend
5
Positive
8
Negative
3
 
SHORT SELL
 
STOCK INFO

HENGRUI PHARMA (01276.HK)  +0.600 (+1.054%)   's subsidiary, Fujian Shengdi Pharmaceutical, received notification from the National Medical Products Administration (NMPA) approving the market launch of its hemofiltration replacement fluid of sodium citrate, as announced by HENGRUI PHARMA.

The medication can be used as a replacement fluid for continuous renal replacement therapy (CRRT) employing regional citrate anticoagulation. Citrate is particularly suitable for situations where systemic anticoagulation with heparin is contraindicated, such as in patients with increased bleeding risk.

Related NewsCICC Lists A-shr Companies that May List on H-shr Mkt Soon (Table)
The product's approval is considered equivalent to passing the generic drug quality and efficacy consistency evaluation, the Company added. As of now, the total R&D investment for the hemofiltration replacement fluid of sodium citrate project was approx. RMB8.57 million.
(HK stocks quote is delayed for at least 15 mins.)

AASTOCKS Financial News
Website: www.aastocks.com
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.